Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Year: 2026
Type: article
Abstract: Chimeric antigen receptor (CAR) T-cell therapy has reshaped the therapeutic landscape for multiple myeloma, yet most patients treated with BCMA-targeted CAR T cells experience disease relapse. Consequently, we sought to determine if inhibition of CD28 survival signaling could increase multiple myeloma sensitivity to CAR T-cell therapy. Contrary to expectations, blockade of CD28 interaction with CD80/86 accelerated tumor regrowth in preclinical multiple myeloma and lymphoma CAR T-cell therapy models. Knockout studies revealed that endogenous CD28 on 4-1BB costimulated CAR T cells prolonged in vivo activity, reprogrammed mitochondrial metabolism to maintain redox balance, and stimulated proliferation and release of tumor model-specific inflammatory cytokines in the tumor microenvironment (TME). Intriguingly, transient CD28 blockade decreased levels of certain TME cytokines without significantly affecting survival of CAR T cell-treated mice. Collectively, these data provide direct evidence that endogenous CD28 signaling modulates CAR T-cell responses in multiple myeloma and lymphoma models. SIGNIFICANCE: This study provides direct evidence that endogenous CD28 on 4-1BB costimulated CAR T cells promotes cytotoxic activity and the production of inflammatory cytokines in the TME. These findings have important implications for ongoing efforts to improve CAR T-cell therapy for the treatment of hematologic malignancies. See related commentary by Hamieh and Sadelain, p. 343.
Source: Blood Cancer Discovery
Authors: Mackenzie M. Lieberman, Jason H. Tong, Nkechi U. Odukwe, Colin A. Chavel, Gina G. Bishara, Kimberly M. Crasti, Megan M. Herr, Payal Goala, Terence J. Purdon, Rebecca Burchett, Bryan M. Gillard, Craig M. Brackett, Joseph D. Tario, Spencer R. Rosario, A.J. Robert McGray, Jonathan L. Bramson, Marco L. Davila, Renier J. Brentjens, Ehsan Malek, Kelvin P. Lee, Scott H. Olejniczak
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: Examining the impact of endogenous CD28 signaling on CAR T cells, IVIS Spectrum Imaging System, Multidisciplinary Approaches to Tumor Immunology, Understanding mechanisms and consequences of T cell co-receptor regulated RNA maturation, Modulating costimulation in CAR T cells to enhance antitumor efficacy, Roswell Park Cancer Center Support Grant
OpenAlex ID: W7127067105
